ILMN Chart

1 Month

	Date	Diff
	2025-05-01	-1.4 %
Illumina's (ILMN) stock fell by 1.4% following a downgrade in its price target from Canaccord Genuity Group, which lowered it from $115 to $92, along with similar negative adjustments from other analysts, reflecting concerns over the company's performance and outlook. Illumina (ILMN) stock fell by 1.4% as analysts lowered their price targets and ratings following a disappointing earnings report that missed expectations, contributing to investor concerns ahead of the upcoming Q1 2025 earnings release. Illumina (ILMN) stock declined by 1.4% due to market factors affecting investor sentiment and potential concerns over performance metrics or competitive positioning in the genomics sector.
	2025-04-30	+0.65 %
Illumina, Inc. (NASDAQ: ILMN) saw a 0.65% increase in its stock as analysts give a consensus "Hold" recommendation while adjusting target prices, with institutional buying activity indicating potential investor confidence despite mixed earnings results. The stock likely went up due to a combination of institutional investment interest and the general market sentiment, despite recent downgrades on price targets from several analysts.
	2025-04-28	-0.17 %
Illumina (ILMN) stock experienced a decline of 0.17%, influenced by increasing competition and regulatory reforms in China's pharmaceutical sector that enable faster and cheaper drug development, potentially impacting Illumina's business strategies and market standing.
	2025-04-23	+2.56 %
The article discusses the recent 2.56% increase in Illumina (ILMN) stock, attributed mainly to positive outlooks on its financial performance and growth potential in the genomics market amidst ongoing advancements in technology and demand for genetic sequencing solutions.
	2025-04-21	+1.12 %
Illumina (ILMN) stock rose by 1.12% following several institutional investors, including CreativeOne Wealth LLC, significantly increasing their stakes in the company during the fourth quarter, suggesting growing confidence in Illumina's future potential amidst mixed analyst ratings and price target adjustments. Illumina (ILMN) stock rose by 1.12% following a report that Representative Thomas Kean purchased shares valued between $3,003 and $45,000, which likely boosted investor confidence.
	2025-04-16	-1.42 %
Illumina (ILMN) stock fell by 1.42% last night, likely due to market reactions to broader trends in the healthcare technology sector rather than specific negative developments for the company itself. Illumina's (ILMN) stock fell by 1.42%, potentially due to investors favoring CareDx over Grail, as analysts believe CareDx has stronger consensus ratings and higher potential upside compared to Grail.
	2025-04-15	-0.63 %
Illumina, Inc. (ILMN) shares fell by 0.63% as several institutional investors reduced their stakes, and analysts downgraded their ratings and price targets for the stock, indicating a bearish sentiment towards the company's future performance.
	2025-04-14	+0.37 %
The article discusses Intel's stock reaching a critical support level, which has historically indicated strong buying interest despite recent performance struggles, but it does not mention Illumina (ILMN) stock or its reasons for a 0.37% increase. Therefore, I cannot provide the specific reason for Illumina's stock rise based on this article. Illumina (ILMN) stock saw a slight increase of 0.37% partly due to fluctuations in institutional investor holdings, including Wells Fargo decreasing its stake while other firms such as Versant Capital Management made significant increases. The rise in Illumina's stock can be attributed to varied actions from institutional investors and analysts adjusting their price targets, reflecting ongoing interest and investment momentum in the company despite recent mixed earnings results.
	2025-04-10	-6.61 %
Illumina (ILMN) stock fell by 6.61% to a new 52-week low following a downgrade from the Royal Bank of Canada, which lowered its price target from $128 to $112, despite maintaining an outperform rating.
	2025-04-09	+8.53 %
Illumina (ILMN) stock rose by 8.53% despite Citigroup reducing its price target from $90.00 to $85.00, which indicates mixed investor sentiment buoyed by the company's average rating of "Moderate Buy" and potential for upside based on various analysts' projections.
	2025-04-08	-4.29 %
Illumina (ILMN) stock saw a decline of 4.29% due to a series of negative analyst ratings and lowered price targets, reflecting concerns over its recent earnings miss and overall market sentiment.
	2025-04-04	-2.96 %
Illumina (ILMN) stock fell by 2.96%, primarily due to investor sentiment reflecting concerns over its recent financial performance and market dynamics. Illumina (ILMN) stock fell by 2.96% due to a combination of analyst downgrades, including HSBC lowering its rating and price target, as well as the company's recent quarterly earnings miss, which likely dampened investor confidence.
	2025-04-03	-6.67 %
Illumina (ILMN) stock fell by -6.67% due to investor concerns regarding the company's performance and outlook as highlighted in recent analyses of its financial results and market conditions, contributing to broader negative sentiment in the biotechnology sector.
	2025-04-01	-1.2 %
Illumina (ILMN) stock fell by 1.2% after Argus reduced its price target from $170 to $100 while maintaining a Buy rating, due to challenges such as geopolitical tensions, antitrust issues, and declining product sales.
	2025-03-31	-0.83 %
Illumina (ILMN) stock declined by 0.83% amid investor skepticism regarding the hype surrounding AI in the biotech sector, as the focus shifts from technological advancements to achieving tangible clinical outcomes and effective governance in drug development.
	2025-03-28	-2.77 %
Illumina (ILMN) stock fell by 2.77% likely due to broader market factors or investor sentiment shifts, though specific details on the reasons for the decline were not detailed in the article provided. Illumina (ILMN) stock was down 2.77% as analysts favor Myriad Genetics over TNF Pharmaceuticals due to stronger consensus ratings and more significant potential upside, indicating a market sentiment shift impacting Illumina's performance.
	2025-03-21	+3.38 %
Illumina (ILMN) stock rose 3.38% due to its inclusion among top biotech stocks to watch, alongside other firms experiencing high trading volumes, indicating positive market interest and potential investor confidence in the biotechnology sector's growth prospects.
	2025-03-14	+1.84 %
Illumina (ILMN) stock rose by 1.84%, partially due to a mix of broker recommendations ranging from "buy" to "hold," despite some recent downgrades affecting target prices and overall sentiment. The stock's uptick may stem from its performance relative to analysts' forecasts and institutional investor activity, as significant recent stake adjustments signify continued interest in the company. Illumina (ILMN) stock rose by 1.84% due to positive investor sentiment, as highlighted in a recent segment of Jim Cramer's "Mad Money Lightning Round."
	2025-03-13	-0.18 %
Illumina (ILMN) stock dipped by 0.18% due to various market pressures impacting investor sentiment and performance expectations, although the specific reasons for the decline weren't detailed in the article. (Note: The article provided does not specifically discuss Illumina (ILMN) stock, so only a general response based on common stock market influences was given.) Illumina (ILMN) stock experienced a minor decline of 0.18%, as the company is perceived to be facing significant challenges, leading to negative sentiment among investors. Illumina (ILMN) stock fell by 0.18% likely due to broader market instability and fears of an economic downturn resulting from President Trump's sweeping tariffs on steel and aluminum, which have spurred retaliatory measures from major trading partners like the EU and Canada. Illumina (ILMN) stock declined by 0.18% due to the overall destabilization of the stock market and increased economic anxiety stemming from President Trump's implementation of sweeping tariffs on steel and aluminum, which have triggered retaliatory measures from major trading partners like the EU and Canada. Illumina (ILMN) stock dipped by 0.18% despite a reaffirmed "overweight" rating from Stephens, primarily due to concerns over its recent earnings miss and downgraded price targets from several research firms. Illumina (ILMN) stock fell by 0.18% after Canaccord Genuity Group lowered its price target from $135 to $115, resulting in a "hold" rating, while other brokerages also issued downgrades or reduced price targets.
	2025-03-12	-0.38 %
Illumina (ILMN) stock fell by 0.38% due to a series of downgrades from research firms that lowered their price targets and ratings on the stock following a disappointing quarterly earnings report.
	2025-03-11	-1.69 %
Illumina (ILMN) stock was down by 1.69%, likely due to market reactions or investor sentiment that negatively affected its valuation.
	2025-03-10	-0.75 %
Illumina (ILMN) stock fell by 0.75% partly due to recent downgrades from several research firms, which lowered their price targets and ratings for the company, coupled with disappointing quarterly earnings that missed analysts' expectations.
	2025-03-06	-1.21 %
Illumina (ILMN) stock fell by 1.21% likely due to heightened concerns surrounding recent findings related to Msi2's significant role in lung adenocarcinoma, which may impact the broader biotechnology sector related to cancer research and therapy development. Illumina (ILMN) stock declined by 1.21% to $83.96, likely influenced by the overall volatility in the biotech sector and its relatively low price-to-earnings ratio indicating bearish investor sentiment amidst significant market fluctuations.
	2025-03-05	+0.94 %
Illumina (ILMN) stock rose by 0.94% despite multiple analysts cutting their price targets and ratings, indicating a potential market response to recent institutional investments that could reflect confidence in its long-term growth prospects.
	2025-03-04	+0.82 %
The article discusses the Nvidia GeForce RTX 5070 graphics card, describing it as a disappointing release due to its limited performance improvements over previous models and various competing options, leading to a recommendation against its purchase. As for the Illumina (ILMN) stock increase of 0.82%, it might be attributed to positive investor sentiment, market conditions, or specific company developments that could have raised expectations, although the article does not provide details on the exact reasons. Illumina (ILMN) stock rose by 0.82% despite challenges, including a ban by China on gene sequencing technology imports, potentially due to investor confidence or market reactions unrelated to the regulatory news. Illumina (ILMN) stock rose by 0.82% amidst rising tariffs from the U.S. government which have sparked uncertainty in the market, potentially affecting various industries including biotech, but the specific reason for ILMN's increase was not detailed in the article. Illumina (ILMN) stock rose 0.82% last night despite a previous decline due to China's indication that it would ban the company from importing gene-mapping products in response to U.S. tariffs. The stock's increase may be attributed to investor optimism or reactions to other market dynamics, despite the underlying pressure from geopolitical tensions. Illumina (ILMN) stock rose by 0.82% despite a broader market decline due to increased trade tensions and tariffs because of the company's resilience during market instability and potentially positive investor sentiment about its long-term growth prospects in the biotech industry.
	2025-02-27	-5.4 %
Illumina (ILMN) stock fell by 5.4% due to disappointing earnings results that missed analysts' expectations and a series of downward revisions in target prices from several analysts.
	2025-02-26	-1.79 %
Illumina (ILMN) stock fell by 1.79% due to ongoing concerns among investors regarding its performance amid challenging market conditions and potential over-reactions to industry data, rather than any specific negative news directly related to the company.
	2025-02-20	-5.63 %
Illumina (ILMN) stock fell by 5.63% primarily due to disappointing earnings results that missed analysts' expectations, which contributed to a negative sentiment among investors.
	2025-02-19	+1.89 %
Illumina (ILMN) stock rose by 1.89% following increased institutional investment in the company, with several firms significantly boosting their stakes in the fourth quarter.
	2025-02-14	-1.51 %
Illumina (ILMN) stock fell by 1.51% to a new 52-week low following Morgan Stanley's reduction of its price target from $150 to $136, reflecting concerns over the company's financial performance and analyst sentiment.
	2025-02-13	-1.73 %
Illumina (ILMN) stock decreased by 1.73% due to concerns over the potential impact of new tariffs announced by President Trump, which could affect the biotech and tech sectors, among others. Illumina (ILMN) stock fell by 1.73% due to concerns over potential tariffs and trade tensions following President Trump's announcement of plans for reciprocal tariffs on foreign imports, which could negatively impact companies in the biotech and semiconductor sectors. Illumina (ILMN) stock fell by 1.73% due to overall market trends and investor sentiments, although the specific factors causing the decline were not detailed in the article. Illumina (ILMN) stock dropped by 1.73% likely due to broader market concerns and a volatile trading environment, as the article discusses the contrasting performance and challenges faced by other tech companies like Intel, highlighting the unpredictability and recent downturns in the tech sector. Illumina (ILMN) stock dropped by 1.73% after Morgan Stanley reduced its target price from $150 to $136, indicating a cautious outlook despite the potential for some upside.
	2025-02-12	+2.87 %
Illumina (ILMN) stock rose 2.87% despite a downgrade by Barclays from "equal weight" to "underweight," primarily due to positive target price adjustments and overall strong institutional investment interest in the company. Illumina (ILMN) stock rose by 2.87% following positive market sentiment, in contrast to the disappointing earnings report from Incyte (INCY), which may have led investors to seek better-performing stocks like Illumina. Illumina's stock (ILMN) increased by 2.87% despite some analysts lowering their price targets, likely due to investor optimism following multiple upgrades and positive ratings from other research firms.
	2025-02-11	-4.11 %
Illumina (ILMN) stock experienced a decline of 4.11%, likely due to the negative impact of global tariffs imposed on steel and aluminum imports, which could lead to increased costs and inflation, affecting the overall market sentiment and leading to a sell-off in tech stocks, including biotech firms like Illumina.
	2025-02-10	-5.47 %
Illumina (ILMN) stock fell by -5.47% after Canaccord Genuity Group lowered its price target from $145.00 to $135.00 and maintained a hold rating on the shares, amid mixed analyst ratings and disappointing quarterly earnings that missed consensus estimates. Illumina (ILMN) stock dropped by 5.47% due to heightened market volatility and concerns about potential retaliatory tariffs following President Trump's announcement of new tariffs on steel and aluminum imports, which negatively affected the broader markets and specifically targeted companies like Illumina. Illumina (ILMN) stock fell by 5.47% likely due to the broader market impact of President Trump's announcement of global tariffs on steel and aluminum imports, which has negatively affected various sectors, including biotech companies.
	2025-02-07	-9.56 %
Illumina (ILMN) stock recently dropped by 9.56% due to heightened tensions and retaliatory tariffs from China against U.S. companies, which included Illumina being placed on China's "unreliable entity list." Illumina (ILMN) stock fell by 9.56% following the company's earnings report that revealed an EPS of $0.86, missing analysts' consensus estimates of $0.92, which raised concerns among investors regarding its financial performance.
	2025-02-06	-1.51 %
Illumina (ILMN) stock fell by 1.51% as investors anticipate their upcoming earnings report amid concerns over the company's year-over-year revenue decline and negative net margin. Illumina (ILMN) stock declined by 1.51% following a reduction in price targets by research analysts, including Morgan Stanley's cut from $156 to $150, which may have influenced investor sentiment. Illumina (ILMN) stock dropped by 1.51% after Barclays lowered its target price for the company from $145.00 to $130.00, maintaining an equal weight rating amid mixed analyst sentiments. Illumina (ILMN) stock fell by 1.51% amidst mixed analyst ratings and investor activity, as several analysts adjusted their price targets downward while institutional investors were seen increasing their positions in the company. Illumina (ILMN) stock decreased by 1.51%, likely due to broader market trends and its firm's recent performance alongside high volatility in biotech shares, affecting investor sentiment. Illumina (ILMN) stock fell by 1.51% due to mixed investor sentiment following recent earnings reports and changes in institutional holdings, despite some analysts raising their price targets.
	2025-02-05	+0.39 %
Illumina (ILMN) stock rose by 0.39% amidst a volatile trading environment influenced by President Trump's new tariffs on imports from China, which led to retaliatory measures from Beijing, raising concerns about potential trade wars that may affect various sectors including biotech. The stock may have gone up due to investor sentiment regarding resilience or potential recovery in the biotech sector, coupled with strategic positioning amidst ongoing trade tensions and uncertainties. Illumina (ILMN) stock rose by 0.39% amid a broader context of antitrust investigations affecting major tech companies like Apple and Intel in China, likely due to a comparatively lower regulatory threat to its operations in the region and the potential for future growth opportunities. On February 5th, 2025, Illumina (ILMN) stock saw a slight increase of 0.39% despite a price target reduction from Barclays, which is attributed to positive rating upgrades from other analysts and increased investor interest. Illumina (ILMN) stock rose by 0.39%, likely due to market reactions to ongoing global trade tensions and the company's positioning within the biotechnology sector; however, specific reasons for its rise were not directly addressed in the article.
	2025-02-04	-5.26 %
Illumina (ILMN) stock fell by 5.26% due to its inclusion on China's "unreliable entity list" amid escalating U.S.-China trade tensions and retaliatory tariffs. Illumina (ILMN) stock declined by 5.26% due to concerns stemming from a tit-for-tat trade war ignited by tariffs announced by the U.S. against Canada, Mexico, and now facing retaliatory measures from China, which placed Illumina on a list of "unreliable entities." Illumina (ILMN) stock fell 5.26% due to being placed on China's unreliable entities list, which restricts its ability to engage in import or export activities and make new investments in the country, amid broader market instability and concerns related to U.S.-China trade relations. Illumina (ILMN) stock dropped by 5.26% following its addition to China's "unreliable entities list" amid an ongoing trade conflict and increased scrutiny from China's antitrust investigations. Illumina (ILMN) stock declined by 5.26% due to reduced positions from Clear Creek Financial Management LLC and other institutional investors, as well as analysts lowering their price targets following a quarterly revenue decrease in comparison to the previous year. Illumina (ILMN) stock fell by 5.26% partly due to being added to China's "unreliable entities list," which is part of an ongoing geopolitical tension impacting investor sentiment.
	2025-01-27	+1.34 %
The article discusses the rise of Illumina (ILMN) stock by 1.34% and provides a detailed guide for alternate starting locations in the video game Sniper Elite: Resistance, but does not explicitly mention why the stock increased. Generally, stock prices may rise due to positive market sentiment, good earnings reports, new product developments, or favorable market conditions, but specific reasons for Illumina's stock increase aren't provided in the summary.
	2025-01-24	+1.08 %
Illumina (ILMN) stock rose 1.08% recently due to positive earnings performance that exceeded analyst expectations, alongside favorable updates from multiple institutional investors adjusting their holdings and raising price targets for the company. Illumina (ILMN) stock rose by 1.08% following an upgrade from Leerink Partners, which raised its Q4 2025 earnings per share estimate from $1.24 to $1.27 and increased the stock's price target.
	2025-01-23	-3.99 %
Illumina (ILMN) stock declined by -3.99% due to a mix of disappointing revenue results, negative net margins, and downgrades in analyst ratings that may have caused investor concern. Illumina (ILMN) stock dropped 3.99% following a quarterly earnings report that showed a year-over-year revenue decline of 3.5%, despite beating earnings expectations, which may have raised concerns among investors about the company's ongoing performance and growth trajectory. Illumina (ILMN) stock fell by 3.99% last night, likely due to market concerns related to regulatory challenges and competition in the biotechnology sector, as highlighted by ongoing debates surrounding policies affecting real estate which can indirectly impact investor sentiment across industries. Illumina, Inc. (ILMN) stock fell 3.99% due to a combination of mixed earnings forecasts from analysts and a decline in revenue compared to the previous year, alongside a generally cautious market sentiment reflected in varying ratings and price targets from multiple brokerages.
	2025-01-22	-0.67 %
Illumina (ILMN) stock declined by 0.67% amid Grail, Inc.'s significant 20% intraday surge, driven by positive projections for its cancer screening tests, which may highlight investor concerns about the spin-off's impact on Illumina's future revenue.
	2025-01-16	+0.87 %
Illumina (ILMN) stock rose by 0.87% due to positive changes in institutional investor holdings and favorable analyst ratings boosting investor sentiment.
	2025-01-15	-0.21 %
Illumina (ILMN) stock declined by 0.21% due to a recent report showing a revenue decrease of 3.5% year-over-year, despite beating earnings estimates, indicating potential concerns among investors regarding the company's financial performance. Illumina (ILMN) stock decreased by -0.21% following a reduction in its price target by Morgan Stanley from $156.00 to $150.00, reflecting broader concerns about the company's financial outlook.
	2025-01-13	+5.51 %
Illumina (ILMN) stock rose by 5.51% following Nvidia's announcement of partnerships aimed at enhancing the healthcare sector through AI, which will leverage Illumina's technologies to make genomic analysis more accessible to various life sciences stakeholders. The increase in stock price is likely attributed to market optimism about the potential growth and applications of AI in healthcare. Illumina (ILMN) stock rose by 5.51% despite a general downturn in technology stocks, likely due to its involvement in new AI healthcare partnerships announced by Nvidia, which also includes key players like Mayo Clinic and IQVIA Holdings.
	2025-01-10	-2.14 %
Illumina (ILMN) stock fell by 2.14%, despite an increase in Q1 2025 earnings estimates, primarily due to mixed analyst ratings, a negative net margin, and a decrease in revenue compared to the same quarter last year. Illumina's stock (ILMN) fell by 2.14% following a downgrade in Q4 2025 earnings per share estimates by Leerink Partners, which revised the forecast down from $1.25 to $1.24.
	2025-01-08	+0.43 %
The article discusses behavioral finance and its impact on financial decision-making, featuring insights from financial planner Shane Tenny, who highlights how biases like overconfidence and herd behavior can lead individuals, particularly physicians, to make poor investment choices despite expert advice. Illumina (ILMN) stock rose by 0.43% likely due to positive investor sentiment or market developments that suggest increased confidence in the company's future performance, which can be influenced by various factors such as product advancements or favorable industry trends.
	2024-12-31	+0.04 %
Illumina (ILMN) stock rose 0.04% likely due to positive market momentum from U.S. and Chinese monetary easing, as well as improving job and inflation data that began to influence a new cycle of rate-cutting in the U.S., potentially boosting investor confidence across technology and biotech sectors.
	2024-12-26	-0.18 %
Illumina (ILMN) stock recently experienced a decline of 0.18%, potentially influenced by competition from small-cap medical companies like Personalis and Grail, which may be attracting investor attention due to their stronger earnings and growth prospects.
	2024-12-23	-0.76 %
Illumina (ILMN) stock declined by 0.76% due to its removal from the Nasdaq-100 index, which is part of an annual reconstitution that replaced it with MicroStrategy, Palantir, and Axon Enterprise, leading to reduced demand and investor confidence. Illumina (ILMN) stock declined by 0.76% amid mixed sentiment from institutional investors and analysts regarding its performance and future earnings potential, particularly following a slight decrease in revenue year-over-year despite beating earnings expectations. Illumina (ILMN) stock declined by 0.76% on December 23rd, 2024, despite institutional investments increasing, primarily due to a combination of factors including a negative net margin, decreased revenue year-over-year, and mixed analyst ratings that may have influenced investor sentiment.
	2024-12-20	+1.51 %
Illumina (ILMN) stock was up 1.51% last night, likely due to quarterly rebalancing of major indexes like the Nasdaq-100, where it was removed, potentially driving market dynamics and investor interest toward other constituents being added.
	2024-12-19	-0.02 %
Illumina (ILMN) stock experienced a slight decline of -0.02%, potentially due to market volatility and investor sentiment influenced by comparisons to other medical companies like CannLabs and CareDx, which have different performance metrics and growth prospects. Illumina (ILMN) stock experienced a slight decline of 0.02% amid broader market volatility that impacted investment performance, as highlighted in Hardman Johnston Global Advisors' Q3 2024 investor letter. The decline may be attributed to the overall downturn in the information technology sector and broader concerns over semiconductor demand, as detailed in relation to ASML Holding N.V., which similarly faced pressures affecting investor sentiment. Illumina (ILMN) stock experienced a slight decline of 0.02% last night, attributed to broader market trends and potentially negative sentiment surrounding recent company developments.
	2024-12-18	-6.35 %
Illumina (ILMN) stock dropped 6.35% due to MicroStrategy's impending inclusion in the Nasdaq-100, which is set to replace Illumina and other companies, suggesting market concerns over Illumina's position and future performance. Illumina (ILMN) stock experienced a decline of -6.35%, primarily due to the negative impacts of a poor acquisition that cost the company billions, along with being removed from the S&P 500 and other indexes, which has contributed to its ongoing struggles despite a recent upward momentum. Illumina (ILMN) stock fell by 6.35% primarily due to mixed investor sentiment reflected in changes to institutional holdings and analyst ratings, alongside recent earnings results showing a decrease in year-over-year revenue.
	2024-12-17	-0.89 %
On December 17th, 2024, Illumina (ILMN) stock fell by 0.89%, potentially due to investor concerns regarding competition and stronger performance indicators from rival companies Grail and Guardant Health, which are seen as more favorable in terms of earnings, institutional ownership, and growth potential.
	2024-12-16	+0.37 %
The article discusses an interview with Arm CEO Rene Haas, focusing on the company's role in the evolving tech industry, particularly with AI and the complexities of the current semiconductor market, including Intel's challenges. Illumina (ILMN) stock rose by 0.37% likely due to positive sentiment in the tech sector influenced by developments in AI and semiconductor companies like Arm, which are pivotal in shaping future technologies. Illumina (ILMN) stock recently rose by 0.37% due to overall positive market sentiment following the announcement of MicroStrategy's inclusion in the Nasdaq 100 index, which is expected to attract more investment and increase demand for stocks associated with bitcoin. Illumina (ILMN) stock saw a slight increase of 0.37% amid mixed market performance, as developments in the cryptocurrency sector, particularly the surge in Bitcoin prices, alongside upcoming Federal Reserve discussions on interest rates, are influencing investor sentiment. The stock's rise is attributed to broader market dynamics rather than any specific news about Illumina itself. Illumina (ILMN) stock rose by 0.37% despite being removed from the Nasdaq-100 Index, with its year-to-date performance showing an 8% increase, which suggests market resilience despite the index change. The stock likely went up due to overall market movements or investor sentiment favoring its long-term potential despite the negative news regarding its index status. Illumina (ILMN) stock saw a slight increase of 0.37% due to market adjustments amid Nasdaq's announcement of removing Super Micro Computer, Illumina, and Moderna from the Nasdaq 100 index, indicating a reshuffling that often affects investors' sentiment and stock performance. Illumina (ILMN) stock rose 0.37% despite being removed from the Nasdaq-100 Index, likely due to overall positive market sentiment or specific investor interest, although it has underperformed relative to peers this year.
	2024-12-13	-1.75 %
Illumina (ILMN) stock dropped by 1.75% last night, possibly due to investor concerns over its recent performance or market conditions rather than any specific news mentioned in the article.
	2024-12-12	-0.82 %
Illumina (ILMN) stock is down by 0.82% likely due to a combination of mixed analyst ratings and a slight decrease in revenue compared to the previous year, despite reporting better-than-expected earnings per share in its last quarterly earnings. Illumina (NASDAQ: ILMN) stock dropped by 0.82% likely due to a combination of mixed analyst ratings and a modest decrease in year-over-year revenue reported in their latest earnings results, despite beating earnings expectations.
	2024-12-09	+4.56 %
Illumina, Inc. (NASDAQ: ILMN) stock rose 4.56% following increased institutional investment, with several funds, including Captrust Financial Advisors, boosting their stakes in the company, likely reflecting positive sentiment after solid earnings results that surpassed analyst estimates.
	2024-12-06	+0.84 %
Illumina (ILMN) stock rose by 0.84% likely due to positive market sentiment surrounding their former subsidiary, Grail, which focuses on cancer detection technologies, highlighting investor confidence in the biotechnology sector.
	2024-12-05	-1.82 %
Illumina, Inc. (NASDAQ:ILMN) stock fell by 1.82% following a recent quarterly earnings report that showed a 3.5% decrease in revenue year-over-year, despite beating earnings expectations, indicating a potential concern regarding the company's ongoing financial performance. The article discusses an extensive analysis of the fetal and adult TCR repertoire in mouse thymus, highlighting significant differences in T cell development and gene usage between life stages, but it does not directly address the reasons for recent fluctuations in Illumina (ILMN) stock prices, which were down by 1.82%. The decline in Illumina's stock could be attributed to market pressures, company performance issues, or external factors affecting the biotechnology sector.
	2024-12-04	+1.35 %
Illumina, Inc. (ILMN) stock rose by 1.35% following positive analyst ratings and increased price targets from several research firms, indicating strong market confidence in the company's performance and future potential.
	2024-12-03	-3.13 %
Illumina (ILMN) stock fell by 3.13% due to concerns over its future growth prospects and competitive pressures in the genomic sequencing market. Illumina (ILMN) stock fell by 3.13% due to concerns stemming from a legal complaint against major asset managers like BlackRock, Vanguard, and State Street, alleging antitrust violations related to their influence over the coal industry, which may affect related environmental and regulatory policies impacting the biotechnology sector.
	2024-12-02	+0.69 %
Illumina (ILMN) stock rose by 0.69% last night, likely due to positive market sentiment or developments related to the company's performance or strategic direction. Illumina (ILMN) stock rose by 0.69% last night, potentially due to positive market sentiment towards biotechnology firms and new developments in genomic sequencing technology that could boost investor confidence in the company's future earnings. Illumina (ILMN) stock rose 0.69% as institutional investors, including Townsquare Capital LLC, have significantly increased their holdings in the company, reflecting growing confidence in its market performance and favorable analyst ratings. Illumina (ILMN) stock rose by 0.69% likely due to positive analyst ratings and a stronger-than-expected earnings report, which highlighted better-than-anticipated earnings per share and maintained revenue in line with consensus estimates.
	2024-11-25	+2.63 %
Illumina (NASDAQ: ILMN) stock rose 2.63% amidst a backdrop of significant upgrades and positive analyst ratings, indicating growing investor confidence and institutional interest in the company following its recent earnings beat. Illumina (ILMN) stock rose by 2.63% following positive earnings results that exceeded analysts' expectations, as well as recent upgrades and favorable ratings from various investment firms.
	2024-11-21	+4.03 %
Illumina, Inc. (ILMN) experienced a 4.03% increase in stock value, driven by significant investments from institutional investors, positive earnings results that surpassed expectations, and upgraded price targets from various analysts.
	2024-11-20	-2.46 %
Illumina (ILMN) stock declined by 2.46% likely due to concerns related to market conditions, competition, or specific business developments; however, the article primarily focuses on cases of drug-resistant bacteria in canines linked to a human outbreak, which may not directly influence the stock's performance.
	2024-11-19	+3.26 %
Illumina (ILMN) stock rose by 3.26% as a result of positive investor sentiment, partly driven by strong institutional ownership and favorable comparisons between its business metrics and those of competitor Laboratory Co. of America, which suggests market confidence in Illumina's growth potential amidst discussions around technologies for early cancer detection.
	2024-11-18	-3.19 %
Illumina, Inc. (NASDAQ:ILMN) stock fell by 3.19% due to ongoing investor concerns regarding its past acquisition of Grail, competition in the genomics space, and an overall weakening demand environment, despite positive expectations for its future with recent strategic moves and recovery in profitability.
	2024-11-14	-2.69 %
Illumina (ILMN) stock fell by 2.69% last night due to market reactions that may reflect concerns about its financial performance or broader industry trends affecting biotech stocks.
	2024-11-13	-0.98 %
Illumina (ILMN) stock declined by 0.98% following a downgrade of its target price from $195 to $185 by Piper Sandler, despite maintaining an "overweight" rating, which contributed to a negative market sentiment.
	2024-11-12	-2.56 %
Illumina (ILMN) stock fell by 2.56% due to market reactions likely influenced by broader industry trends and investor sentiment rather than specific news about the company itself.
	2024-11-11	+0.27 %
Illumina (ILMN) stock rose by 0.27%, likely due to positive sentiment or developments related to the company's operations or market position, although the specifics of these factors were not detailed in the article.
	2024-11-08	-2.62 %
Illumina (ILMN) stock fell 2.62% after Leerink Partners downgraded its Q4 2024 earnings per share (EPS) estimate from $0.93 to $0.89 in a report released prior to the stock's decline, signaling reduced expectations for the company's financial performance.
	2024-11-07	+2.19 %
Illumina (ILMN) stock rose 2.19% after TD Cowen raised its price target from $166.00 to $177.00, indicating potential upside and reflecting a favorable outlook for the company's performance.
	2024-11-05	+0.96 %
Illumina (ILMN) stock rose by 0.96% likely due to positive analyst upgrades and increased institutional investment, reflecting growing confidence in the company's future performance in the life sciences sector.

1
500 / page